New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 23, 2014
08:57 EDTAMAGAMAG Pharmaceuticals price target lowered to $30 from $43 at Summer Street
Summer Street lowered its price target for AMAG Pharmaceuticals to $30 following the company's complete response letter for a broader indication of Feraheme. The firm keeps a Buy rating on the stock.
News For AMAG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 28, 2015
12:21 EDTAMAGAMAG Pharmaceuticals CRL 'minor and fixable,' says Leerink
Subscribe for More Information
08:02 EDTAMAGAMAG receives complete response letter from FDA for Makena
Subscribe for More Information
May 26, 2015
08:14 EDTAMAGBoston Biotech Conferences to hold a conference
Subscribe for More Information
May 18, 2015
06:55 EDTAMAGAMAG Pharmaceuticals price target raised to $85 from $60 at Leerink
Leerink raised its price target for AMAG Pharmaceuticals to $85 on expectations the 1mL vial formulation will help accelerate Makena's market share gain. The firm reiterates an Outperform rating on the stock.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use